In the LEAN trial, the efficacy of 48 weeks of liraglutide, a GLP-1 RA, was investigated with NASH regression without worsening of fibrosis as the primary endpoint. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.